According to Intercept Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $0.31 B. In 2022 the company made a revenue of $0.31 B a decrease over the years 2021 revenue that were of $0.36 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.31 B | 0.81% |
2022 | $0.31 B | -13.29% |
2021 | $0.36 B | 16.24% |
2020 | $0.31 B | 24.08% |
2019 | $0.25 B | 40.15% |
2018 | $0.17 B | 37.3% |
2017 | $0.13 B | 424.85% |
2016 | $24.95 M | 796.74% |
2015 | $2.78 M | 59.83% |
2014 | $1.74 M | 7.35% |
2013 | $1.62 M | -33.69% |
2012 | $2.44 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Eli Lilly LLY | $34.12 B | 10,641.52% | ๐บ๐ธ USA |
Gilead Sciences GILD | $27.11 B | 8,435.21% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | 14,066.91% | ๐บ๐ธ USA |
MediciNova MNOV | $1 M | -99.69% | ๐บ๐ธ USA |